Cyteir raises $29M series B

Cyteir Therapeutics Inc. (Cambridge, Mass.) raised $29 million in a series B round led by Venrock on March 8. Existing investor Celgene Corp. (NASDAQ:CELG) participated alongside new investors Lightstone Ventures and DROIA Oncology Ventures.

Cyteir plans to begin clinical studies next year of its small molecule inhibitors of RAD51 homolog (RAD51) in cancer indications. ...